Literature DB >> 17045206

p53 family members in myogenic differentiation and rhabdomyosarcoma development.

Hakan Cam1, Heidi Griesmann, Michaela Beitzinger, Lars Hofmann, Rasa Beinoraviciute-Kellner, Markus Sauer, Nicole Hüttinger-Kirchhof, Claudia Oswald, Peter Friedl, Stefan Gattenlöhner, Christof Burek, Andreas Rosenwald, Thorsten Stiewe.   

Abstract

The p53 family comprises the tumor suppressor p53 and the structural homologs p63 and p73. How the three family members cooperate in tumor suppression remains unclear. Here, we report different but complementary functions of the individual members for regulating retinoblastoma protein (RB) function during myogenic differentiation. Whereas p53 transactivates the retinoblastoma gene, p63 and p73 induce the cyclin-dependent kinase inhibitor p57 to maintain RB in an active, hypophosphorylated state. DeltaNp73 inhibits these functions of the p53 family in differentiation control, prevents myogenic differentiation, and enables cooperating oncogenes to transform myoblasts to tumorigenicity. DeltaNp73 is frequently overexpressed in rhabdomyosarcoma and essential for tumor progression in vivo. These findings establish differentiation control as a key tumor suppressor activity of the p53 family.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045206     DOI: 10.1016/j.ccr.2006.08.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  57 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

Authors:  Wendy Roeb; Antonia Boyer; Webster K Cavenee; Karen C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

3.  p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.

Authors:  Michaela Beitzinger; Lars Hofmann; Claudia Oswald; Rasa Beinoraviciute-Kellner; Markus Sauer; Heidi Griesmann; Anne Catherine Bretz; Christof Burek; Andreas Rosenwald; Thorsten Stiewe
Journal:  EMBO J       Date:  2008-01-31       Impact factor: 11.598

4.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

Review 5.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

6.  Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Stephen Qualman; James Lynch; Julia Bridge; David Parham; Lisa Teot; William Meyer; Alberto Pappo
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

7.  A gene signature-based approach identifies mTOR as a regulator of p73.

Authors:  Jennifer M Rosenbluth; Deborah J Mays; Maria F Pino; Luo Jia Tang; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

8.  Maged1, a new regulator of skeletal myogenic differentiation and muscle regeneration.

Authors:  Tuan H N Nguyen; Mathieu J M Bertrand; Christiane Sterpin; Younes Achouri; Olivier R Y De Backer
Journal:  BMC Cell Biol       Date:  2010-07-20       Impact factor: 4.241

9.  Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Authors:  Elizabeth M Algar; Andrea Muscat; Vinod Dagar; Christian Rickert; C W Chow; Jaclyn A Biegel; Paul G Ekert; Richard Saffery; Jeff Craig; Ricky W Johnstone; David M Ashley
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

10.  Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Authors:  Stephan Emmrich; Weiwei Wang; Katja John; Wenzhong Li; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2009-08-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.